Form 4: Serina Therapeutics Director Acquires Shares

Serina Therapeutics, Inc. reports a transaction where Director Venkatesan Jay acquired 7,553 shares of common stock.

Summary

• Director Venkatesan Jay acquired 7,553 shares of Serina Therapeutics, Inc. common stock on March 31, 2026.
• The acquisition was for the payment of accrued dividends on a Convertible Preferred Stock issued on April 8, 2025.
• The acquisition price was $1.94 per share.
• Following this transaction, Venkatesan Jay beneficially owns 7,553 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard dividend payment to a director rather than a new investment or sale.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition was for accrued dividends, indicating a mechanism for compensating preferred shareholders.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition by a director, are common disclosures in the biotechnology and pharmaceutical sectors as companies navigate funding rounds and dividend accruals.

Related Party Transactions

• Acquisition of 7,553 shares of common stock by Director Venkatesan Jay for payment of accrued dividends on Convertible Preferred Stock.

Stakeholder Impact

• Shareholders: This transaction represents a standard dividend payment mechanism for preferred stock, which is a common practice.
• Management: Confirms a director is receiving compensation in the form of stock for accrued dividends.

Key Dates

Keywords

Serina Therapeutics, Form 4, Insider Transaction, Director, Common Stock, Convertible Preferred Stock, Dividends